Is Peptide Sciences Legit? Its Closure, COAs and Record

Peptide Sciences was one of the best-known names in the "research peptide" market — and in March 2026 it closed. People still search for it every month, usually asking one of two things: was it legitimate, and is anything sold under its name today the real thing? This page answers both from primary records only: the company's own archived website, its published lab reports, and the public enforcement databases. It is not a review and carries no score.

What happened to Peptide Sciences

The company's closure comes from its own words. The Internet Archive's captures of its homepage show a working store in early January 2026. By March 8, 2026, the same page had been replaced by a short notice: "After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products."¹ A later version, still up in captures from September 2026, adds that anyone "claiming to sell our products is unauthorized, fraudulent, and has no affiliation with our company."¹

The notice gives no reason. One public document does offer one: a complaint Eli Lilly filed in August 2026 against a different seller describes Peptide Sciences as "a peptide seller that shut down due to FDA enforcement pressures."⁹ That is one party's description in a lawsuit, not a finding by a court or by the FDA. As the enforcement section below shows, no FDA warning letter or DOJ press release names the company.

So the honest status is narrow but clear: the company says it stopped selling, its website stopped taking orders, and the notice has stayed up for months. Nothing in the public record says why, and nothing says it reopened.

What the company's own site claimed

Before the closure, the site's headline offer was "Buy Peptides for Scientific Research and Development," with "99%+ Purity Guaranteed!" on the homepage and claims that its products were "manufactured in the USA" through "WHO/GMP and ISO 9001:2015 approved manufacturers."¹ The footer listed a business address in Boca Raton, Florida, and stated that "all products on this site are for Research, Development use only. Products are Not for Human consumption of any kind." Its terms went further: "IN-VITRO LABORATORY RESEARCH USE ONLY-- NOT FOR HUMAN USE."¹

That "research use only" line is the legal frame of the whole market, and it is worth knowing what it does and does not do. In federal regulations, the phrase "For Research Use Only" comes from the labeling rules for in-vitro diagnostic products — lab test kits, not injectable compounds¹⁰¹¹. When FDA has written to peptide sellers, it has treated the label as beside the point when the surrounding evidence shows human use: "Despite statements on your product labeling marketing your products as 'RESEARCH USE ONLY'... evidence obtained from your websites establish that your products are intended to be drugs for human use."³ Federal prosecutors have gone further in other cases, describing "research/laboratory use only" disclaimers on a peptide seller's website as "a ruse to avoid FDA scrutiny."⁶⁷ None of those cases involved Peptide Sciences; they show how regulators read the label.

Did it publish batch-specific COAs?

Yes — and the reports were better than most in this market. Archived product pages carried two tabs, "COA / HPLC / MS" and "3rd Party Testing."¹ Run through the five checks in our guide to how to verify a peptide COA, the two layers score differently.

The in-house certificate for a BPC-157 lot listed a lot number, an HPLC purity of 98.3% against a >98% specification, and a mass-spectrometry result of 1419.30 Da against the expected 1419.55 ±1.0 Da. It also reported net peptide content, solvent residues and endotoxin. What it lacked was a test date and a named laboratory; it was signed only with a first name and an initial.

The third-party report for another BPC-157 lot came from Frontage Laboratories, a contract lab in Exton, Pennsylvania. It named the client, product and lot, reported HPLC purity of 98.8%, a mass-spectrometry weight of 1419.0 Da, and printed the chromatogram. It was signed and dated September 12, 2025. It also measured 18.27 mg of peptide in a vial labeled 15 mg — about 22% more than stated, which is a dosing error waiting to happen for anyone measuring by the label.

Two layers is the right idea. A certificate written by the seller is the seller grading its own work; a report written by an outside lab, naming the client and the lot, is a second party putting its name on the result. The overfill is the less obvious lesson. A purity figure tells you what share of the powder is the peptide; it says nothing about how much powder is in the vial. Net-content testing is what catches a vial that holds a fifth more — or a fifth less — than its label, and many certificates in this market leave it out.

The one check neither layer passes is independent lookup: the reports were images hosted by the seller, with no report code to confirm on the lab's own website. That matters more now than it did before March, because the company itself says nothing sold under its name is authorized.

Enforcement record: what the primary sources show

This section uses only primary records, matched on the company name and its Boca Raton address — never on a similar-sounding name.

• •FDA warning letters. A full-text search of FDA's warning-letter database for the company name, its trading name and its street address returns no letter². The database does contain letters to other "research use only" peptide sellers, including one in August 2026 to a seller of a retatrutide product called "GLP-3R"⁴ — but none to Peptide Sciences.
• •DOJ press releases. No Department of Justice press release names the company.
• •Federal court records. In the CourtListener archive of federal dockets, the company is not a party to any case⁸. Its only appearances are passing mentions, such as the Lilly complaint quoted above⁹.

The plain reading: the company closed by its own announcement, and no public enforcement action names it. FDA's broader position on this market is public, though. Its consumer page on unapproved GLP-1 drugs says the agency has warned companies selling semaglutide, tirzepatide and retatrutide "falsely labeled 'for research purposes' or 'not for human consumption,'" and that such products may contain "the wrong ingredients," too little, too much, or none at all⁵.

If you see "Peptide Sciences" vials for sale now

Treat them as unverified. The company's own notice calls any seller claiming its products "unauthorized," and any lot sold now cannot be matched to a report the company published.

The closure also created a marketing angle for other sellers. The Lilly complaint says one seller promoted itself as carrying "the same compounds" as Peptide Sciences and marketed to buyers "seeking a replacement seller."⁹ A seller borrowing a closed company's name tells you nothing about what is in its own vials. Ask for that seller's own lot-matched report, and check it the same way. The usual warning signs — recycled certificates, identical purity figures across products, dates that do not add up — are covered in our guide to peptide vendor red flags.

Underneath every one of these sales is the same fact: the compounds themselves are not approved drugs. BPC-157, the market's flagship, sits on FDA's list of bulk substances that may present significant safety risks¹². And when products from this channel are tested, labels often fail: in a JAMA study of 44 products sold online as SARMs — a market with the same "research use only" supply chain — only 23 contained the drug class on the label, and 4 contained no active compound at all¹³. Our guide to where to buy peptides and the research-chemical gray zone covers the legal side in full.

What a licensed prescriber can give you today

If what you wanted from a research vial was a real treatment, a licensed clinician and a state-licensed pharmacy are the regulated route — with a prescription, a pharmacist, and a product made for human use. The difference is not paperwork for its own sake. A pharmacy answers to a state board, a prescriber answers to a medical license, and the product has to be made under standards meant for something that goes into a person. FDA's own advice to consumers buying GLP-1 drugs online is to buy only from state-licensed pharmacies⁵.

• •Weight loss: FDA-approved GLP-1 drugs and prescribed compounded versions are compared in our guide to the best tirzepatide online.
• •Growth-hormone support: sermorelin is prescribed through telehealth clinics — see the best sermorelin online.
• •Recovery: the prescribed options, with anti-doping status, are in our best recovery peptides comparison.
• •Energy and aging: prescribed NAD+ programs are compared in best NAD+ injections.

None of these is a research chemical, and each comes with a clinician who can tell you whether it fits you at all.